Paul Sekhri - Veeva Systems Independent Director
| VEEV Stock | USD 235.85 0.00 0.00% |
Director
Mr. Paul Jai Sekhri is Independent Director of the company. Mr. Sekhri has served as a member of our Board since July 2014. Since February 2016, Mr. Sekhri was Operating Partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Concurrently and since February 2015, Mr. Sekhri was President and CEO of Lycera Corporationration, a biopharmaceutical company. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi S.A., a multinational pharmaceutical company headquartered in France, from April 2014 to January 2015. From May 2013 to March 2014, Mr. Sekhri was Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries, Ltd., a global pharmaceuticals company focusing on the manufacture of generic and proprietary pharmaceutical products headquartered in Israel. From January 2009 to May 2013, Mr. Sekhri was Operating Partner and Head, Biotech Ops Group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG Capital, where he was responsible for a portfolio of more than 50 life sciences companies. From December 2004 to January 2009, Mr. Sekhri was President and CEO of Cerimon Pharmaceuticals, Inc., a pharmaceutical company focusing on autoimmune diseases and pain management. Mr. Sekhri has served as a director of numerous private and public company boards, including Compugen Ltd. since October 2017, Alpine Immune Sciences since July 2017, Pharming N.V. since April 2015, Nivalis Therapeutics, Inc. from February 2016 to July 2017 when it was acquired by Alpine Immune Sciences, Enumeral Biomedical Holdings, Inc. from December 2014, Tandem Diabetes Care Inc. from May 2012 to May 2013, MacroGenics, Inc. from January 2010 to May 2013 and Intercept Pharmaceuticals, Inc. from January 2008 to September 2012. since 2014.
| Age | 62 |
| Tenure | 11 years |
| Address | 4280 Hacienda Drive, Pleasanton, CA, United States, 94588 |
| Phone | 925 452 6500 |
| Web | https://www.veeva.com |
Paul Sekhri Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Sekhri against Veeva Systems stock is an integral part of due diligence when investing in Veeva Systems. Paul Sekhri insider activity provides valuable insight into whether Veeva Systems is net buyers or sellers over its current business cycle. Note, Veeva Systems insiders must abide by specific rules, including filing SEC forms every time they buy or sell Veeva Systems'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Sekhri over six months ago Disposition of 290 shares by Paul Sekhri of Veeva Systems subject to Rule 16b-3 |
Veeva Systems Management Efficiency
The company has return on total asset (ROA) of 0.0657 % which means that it generated a profit of $0.0657 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1363 %, meaning that it created $0.1363 on every $100 dollars invested by stockholders. Veeva Systems' management efficiency ratios could be used to measure how well Veeva Systems manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Veeva Systems' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to climb to 0.12 in 2025, whereas Return On Capital Employed is likely to drop 0.1 in 2025. At this time, Veeva Systems' Fixed Asset Turnover is fairly stable compared to the past year. Return On Assets is likely to climb to 0.12 in 2025, whereas Intangible Assets are likely to drop slightly above 55.5 M in 2025.Similar Executives
| Found 13 records | DIRECTOR Age | ||
| Thomas McKinley | Teladoc | 68 | |
| Karen Daniel | Teladoc | 63 | |
| Mark Smith | Teladoc | 68 | |
| Sandra Fenwick | Teladoc | 69 | |
| William Frist | Teladoc | 69 | |
| Christopher Bischoff | Teladoc | 46 | |
| Kenneth Paulus | Teladoc | 60 | |
| David Shedlarz | Teladoc | 72 | |
| James Bryant | 10X Genomics | N/A | |
| Nikhil Rao | 10X Genomics | N/A | |
| Douglas Hirsch | Goodrx Holdings | 54 | |
| Peter McClennen | Teladoc | 49 | |
| Aubrey Reynolds | Goodrx Holdings | N/A | |
Management Performance
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0657 |
Veeva Systems Class Leadership Team
Elected by the shareholders, the Veeva Systems' board of directors comprises two types of representatives: Veeva Systems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veeva. The board's role is to monitor Veeva Systems' management team and ensure that shareholders' interests are well served. Veeva Systems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veeva Systems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, General VP | ||
| Ato Garrett, Director Relations | ||
| Paul Sekhri, Independent Director | ||
| Matthew Wallach, Co-Founder and Pres | ||
| Timothy Barabe, Independent Director | ||
| Alan Mateo, Executive Vice President of Global Sales | ||
| Pinal Patel, Chief Officer | ||
| Eleni Zuppas, President Staff | ||
| Kristine Diamond, Principal Officer | ||
| Jonathan Faddis, Senior Vice President, General Counsel, Corporate Secretary | ||
| Jacques Mourrain, Regulatory Quality | ||
| Vivian Welsh, Chief Officer | ||
| Timothy Cabral, Interim Director | ||
| Ronald Codd, Independent Director | ||
| Matthew Robinson, Chief Officer | ||
| Peter Gassner, Chief Executive Officer, Director | ||
| Michele OConnor, Principal Accounting Officer | ||
| Frederic Lequient, Senior Vice President - Global Customer Services | ||
| Tina Hunt, Director | ||
| Paul Chamberlain, Independent Director | ||
| Brian Wagener, Chief Officer | ||
| Mark Carges, Independent Director | ||
| Gordon Ritter, Independent Chairman of the Board | ||
| Priscilla Hung, Director | ||
| Gunnar Hansen, Director Relations | ||
| Mary Hedley, Independent Director | ||
| E Zuppas, Chief Marketing Officer | ||
| Brent Bowman, Chief Financial Officer | ||
| Thomas Schwenger, President, Chief Operating Officer | ||
| Marshall Mohr, Director |
Veeva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veeva Systems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0657 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 33.43 B | ||||
| Shares Outstanding | 162.35 M | ||||
| Shares Owned By Insiders | 8.91 % | ||||
| Shares Owned By Institutions | 84.90 % | ||||
| Number Of Shares Shorted | 4 M | ||||
| Price To Earning | 78.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veeva Stock Analysis
When running Veeva Systems' price analysis, check to measure Veeva Systems' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veeva Systems is operating at the current time. Most of Veeva Systems' value examination focuses on studying past and present price action to predict the probability of Veeva Systems' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veeva Systems' price. Additionally, you may evaluate how the addition of Veeva Systems to your portfolios can decrease your overall portfolio volatility.